E2F4-Based Gene Therapy Mitigates the Phenotype of the Alzheimer's Disease Mouse Model 5xFAD
Open Access
- 11 November 2021
- journal article
- research article
- Published by Elsevier in Neurotherapeutics
- Vol. 18 (4) , 2484-2503
Abstract
No abstract availableKeywords
Funding Information
- Ministerio de Ciencia, Innovación y Universidades (RTI2018-095030-B-I00)
- tetraneuron s.l. (N/A)
- Ministerio de Industria (Torres Quevedo)
- Ministerio de Economia, Industria y Competitividad (Industrial Doctorate)
- Consejo Superior de Investigaciones Científicas
This publication has 93 references indexed in Scilit:
- ERK-associated changes in E2F4 phosphorylation, localization and transcriptional activity during mitogenic stimulation in human intestinal epithelial crypt cellsBMC Cell Biology, 2013
- Nerve Growth Factor-Induced Cell Cycle Reentry in Newborn Neurons Is Triggered by p38MAPK-Dependent E2F4 PhosphorylationMolecular and Cellular Biology, 2012
- Wide-ranging functions of E2F4 in transcriptional activation and repression revealed by genome-wide analysisNucleic Acids Research, 2011
- A Phase I Study of Aromatic L-Amino Acid Decarboxylase Gene Therapy for Parkinson's DiseaseMolecular Therapy, 2010
- Selective Cell Death of Hyperploid Neurons in Alzheimer’s DiseaseThe American Journal of Pathology, 2010
- Synapse loss in dementiasJournal of Neuroscience Research, 2010
- E2F4 expression is required for cell cycle progression of normal intestinal crypt cells and colorectal cancer cellsJournal of Cellular Physiology, 2009
- The Neuronal Expression of MYC Causes a Neurodegenerative Phenotype in a Novel Transgenic MouseThe American Journal of Pathology, 2009
- Improving Transcriptional Termination of Self-inactivating Gamma-retroviral and Lentiviral VectorsMolecular Therapy, 2007
- The use of the elevated plus maze as an assay of anxiety-related behavior in rodentsNature Protocols, 2007